The hazard ratio for the death of patients with CD44-positive cancer was 6.8 (95% CI 2.4–19.2, p ≤ 0.001), and carboplatin-resistant or carboplatin-refractory disease was an independent predictor of mortality. Here, CD44 is linked to cancer.